Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy Treatment (Capecitabine) During Radiation Therapy for Rectal Cancer

NCT04406857 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

NIH

Sponsor class

Stopped Inadequate accrual rate

Conditions

Locally Advanced Rectal Carcinoma
Rectal Adenocarcinoma
Stage II Rectal Cancer AJCC v8
Stage III Rectal Cancer AJCC v8

Interventions

DRUG: Capecitabine
RADIATION: Radiation Therapy
DRUG: Ropidoxuridine

Sponsor

National Cancer Institute (NCI)